by Co-Diagnostics | Nov 2, 2020 | News Release
Salt Lake City, Utah – November 2, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that following the discovery of an incorrectly... by Co-Diagnostics | Oct 2, 2020 | Uncategorized
Salt Lake City, Utah – October 2, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that Access Genetics, LLC dba OralDNA® Labs, a... by Co-Diagnostics | Sep 24, 2020 | News Release
Company expects to begin taking orders from US CLIA labs first week of October 2020 Salt Lake City, Utah – September 24, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of... by Co-Diagnostics | Sep 11, 2020 | News Release
Salt Lake City, Utah – September 11, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, today announced the access details for CEO Dwight Egan’s... by Co-Diagnostics | Sep 8, 2020 | News Release
Salt Lake City, Utah – September 8, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the Company), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, today announced that it has entered into an agreement with Arches... 